AMA Webinar Provides Update on COVID-19 Therapeutics and Other Treatment Options

Translate to Spanish or other 102 languages!

Fact-based insights on COVID-19 therapeutic drugs and other treatment options from the nation’s highest-ranking subject matter experts. Image for illustration purposes.
Paxlovid and Molnupiravir—two therapeutics used in treating COVID-19. Image for illustration purposes.

Mega Doctor News

- Advertisement -

The AMA’s COVID-19 webinar series continues this week by bringing the physician community the latest fact-based insights on COVID-19 therapeutic drugs and other treatment options from the nation’s highest-ranking subject matter experts.

During the tenth episode in the webinar series, AMA Immediate Past President Susan R. Bailey, M.D. will host several infectious disease experts from the Food and Drug Administration (FDA) to provide physicians with the most up-to-date information on Paxlovid and Molnupiravir—two therapeutics used in treating COVID-19. They will also discuss alternative treatment options for high-risk outpatients with mild-moderate COVID-19. 

 
What: AMA webinar series, episode 10: therapeutics and other treatment options

When:  Tuesday, February 1, 2022, 1 p.m. Central | 2 p.m. Eastern

Who:   Susan R. Bailey, M.D., AMA Immediate Past President

- Advertisement -

Stephanie Troy, M.D., FDA Senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs

Aimee Hodowanec, M.D., FDA Senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs

John Farley, M.D., M.P.H., FDA Director of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs

Registration: To watch the live webinar, register here

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

Lisraya is the first FDA-approved oral treatment option for patients with dermatomyositis, addressing the high unmet need for this rare disease.

FDA Authorizes First Wearable Device that Continuously Monitors Both Ketone Levels and Blood Sugar

The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.
- Advertisement -